Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunoglobulin G1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Immunoglobulin G1. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-001790-86 Sponsor Protocol Number: PIX306 Start Date*: 2012-12-24
    Sponsor Name:CTI Biopharma, Corp.
    Full Title: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or a...
    Medical condition: Treatment of Patients with Aggressive B-cell Non-Hodgkin Lymphoma , who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    19.1 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) HU (Completed) IT (Completed) CZ (Completed) DK (Prematurely Ended) BG (Prematurely Ended) PL (Completed) BE (Completed) AT (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-000444-26 Sponsor Protocol Number: 17-BI-1206-02 Start Date*: 2018-05-02
    Sponsor Name:BioInvent International AB
    Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractor...
    Medical condition: Indolent B-Cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Ongoing) PL (Prematurely Ended) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000417-33 Sponsor Protocol Number: VIB0551.P3.S2 Start Date*: 2020-09-30
    Sponsor Name:Viela Bio, Inc./Horizon Therapeutics Ireland DAC
    Full Title: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4 Related Disease
    Medical condition: Immunoglobulin G4-related disease (IgG4-RD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10077271 Immunoglobulin G4 related disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) HU (Completed) NL (Trial now transitioned) IT (Trial now transitioned) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000974-44 Sponsor Protocol Number: D910CC00001 Start Date*: 2019-10-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer ...
    Medical condition: Metastatic Microsatellite-Stable Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006657-63 Sponsor Protocol Number: 0881K1-4500-EU (B1801016) Start Date*: 2009-05-08
    Sponsor Name:Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
    Full Title: Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA).
    Medical condition: Rheumatoid Arthritis (RA) patients who are on Etanercept (ETN) treatment and are in remission or in a Low Disease Activity (LDA) state
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed) HU (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2013-000738-36 Sponsor Protocol Number: 20120265 Start Date*: 2013-10-15
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer
    Medical condition: Advanced Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) GR (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003195-39 Sponsor Protocol Number: IM101-301 Start Date*: 2013-08-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juveni...
    Medical condition: Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed) Outside EU/EEA FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-001088-38 Sponsor Protocol Number: BAY80-6946/17833 Start Date*: 2015-12-09
    Sponsor Name:Bayer AG
    Full Title: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in p...
    Medical condition: Patients with relapsed indolent non-Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Completed) DK (Prematurely Ended) ES (Prematurely Ended) GB (Completed) FR (Completed) PL (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) HU (Completed) SK (Prematurely Ended) GR (Completed) BG (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001983-52 Sponsor Protocol Number: GV28985 Start Date*: 2013-09-19
    Sponsor Name:Genentech Inc.
    Full Title: A randomized, double-blind, placebo-controlled, phase 2a study in healthy volunteers, to evaluate the efficacy and safety of MHAA4549A in an Influenza challenge model
    Medical condition: Treatment of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.0 100000004862 10016790 Flu LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001151-12 Sponsor Protocol Number: V114-027 Start Date*: 2018-11-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-D...
    Medical condition: prevention of pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000253-36 Sponsor Protocol Number: CD-IA-MEDI-551-1155 Start Date*: 2014-12-08
    Sponsor Name:MedImmune LLC
    Full Title: A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disord...
    Medical condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) EE (Prematurely Ended) BG (Completed) PL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) GR (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002931-35 Sponsor Protocol Number: D9108C00001 Start Date*: 2019-04-19
    Sponsor Name:MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small...
    Medical condition: Stage III non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000435-41 Sponsor Protocol Number: GOIRC-01-2016 Start Date*: 2016-09-23
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced/Inflammatory HER2...
    Medical condition: HER2-positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023342-67 Sponsor Protocol Number: C38072/3081 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) wit...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004565-14 Sponsor Protocol Number: ECP-002e Start Date*: 2014-02-13
    Sponsor Name:Edimer Pharmaceuticals, Inc.
    Full Title: Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002
    Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1....
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10072592 Hypohidrotic ectodermal dysplasia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male
    Trial protocol: DE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000789-40 Sponsor Protocol Number: D9181C00001 Start Date*: 2020-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants with Uncontrolled Moderate-to-severe Asthma
    Medical condition: Uncontrolled moderate-to-severe asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001663-39 Sponsor Protocol Number: D4190C00022 Start Date*: 2015-11-27
    Sponsor Name:MedImmune
    Full Title: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001847-26 Sponsor Protocol Number: AK002-027 Start Date*: 2023-02-21
    Sponsor Name:Allakos Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneou...
    Medical condition: Chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000461-43 Sponsor Protocol Number: GV29216 Start Date*: 2014-12-22
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION
    Medical condition: Treatment of Influenza
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022002 Influenza A virus infection LLT
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    17.0 100000004862 10016790 Flu LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Completed) HU (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) BE (Completed) NL (Completed) BG (Prematurely Ended) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003681-40 Sponsor Protocol Number: WO42633 Start Date*: 2021-03-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST C...
    Medical condition: Early human epidermal growth factor receptor 2 (HER2) positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 05:49:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA